Novo Nordisk Launches Hemophilia A Treatment NovoEight; Will Compete Directly with Baxter’s Advate

Novo Nordisk Pharma launched on May 12 the recombinant coagulation factor VIII preparation NovoEight (turoctocog alfa) for the treatment of hemophilia A. NovoEight is the second third-generation recombinant coagulation factor VIII product following Baxter’s Advate (rurioctocog alfa). According to Hideji...read more